ALEXIS Biochemicals: Indirubin-3'-monoxime

ALX-270-271

Revised 17-Jul-07

Indirubin-3'-monoxime
PRODUCT LINE	Cell Cycle
PRODUCT CATEGORY	CDK & Cyclin Inhibitors

Ordering Information

Product Numbers:	Format:	Size:	Unit Price:	Quantity:	Add To Cart
ALX-270-271-M001		1 mg	50.00 USD
ALX-270-271-M005		5 mg	190.00 USD

Product Specification

FORMULA:	C₁₆H₁₁N₃O₂
MW:	277.3
PURITY:	≥98% (¹H-NMR)
APPEARANCE:	Dark red powder.
SOLUBILITY:	Soluble in DMSO.
SHIPPING:	AMBIENT
LONG TERM STORAGE:	-20°C

Product Description

Selective and strong inhibitor of cyclin-dependent kinases (CDKs). Inhibits CDK1/cyclin B (IC₅₀=180nM), CDK2/cyclin A (IC₅₀~500nM), CDK2/cyclin E (IC₅₀=250nM), CDK4/cyclin D1 (IC₅₀=3.3µM) and CDK5/p35 (IC₅₀=100nM). Inhibits the proliferation of a large range of cells, mainly through arresting the cells in the G2/M phase of the cell cycle. Powerful inhibitor of GSK-3β (IC₅₀~100nM) and tau phosphorylation in vitro and in vivo at Alzheimer’s disease-specific sites.

Product Specific Literature References

Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases: R. Hoessel, et al.; Nature Cell Biol. 1, 60 (1999) Abstract; Full Text
Anti-mitotic properties of indirubin-3'-monoxime, a CDK/GSK-3 inhibitor: induction of endoreplication following prophase arrest: E. Damiens, et al.; Oncogene 20, 3786 (2001) Abstract; Full Text
Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?: S. Leclerc, et al.; J. Biol. Chem. 276, 251 (2001) Abstract; Full Text
Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells: D. Marko, et al.; Br. J. Cancer 84, 283 (2001) Abstract; Full Text